OBJECTIVE: Medical societies state that fetal fraction (FF) measurements are needed to ensure high accuracy of noninvasive prenatal screening (NIPS) results. While many laboratories rely upon FF to no-call samples below a particular threshold, we apply orthogonal FF measures to reduce the number of false positives (FP). STUDY DESIGN: We evaluated FF discordance (FFD) in putatively aneuploid samples between two measurements of FF that are available via whole-genome-sequencing-based NIPS. One measurement, FFpos, is the relative change in next-generation sequencing depth on the potentially aneuploid chromosome. The other measurement, FFinf, is inferred FF via regression of binned depth across all autosomes.
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We performed a two-phase study on suspected FPs where FFpos << FFinf (Class I FFD). In the training phase, we analyzed 51,514 samples to establish criteria for flagging Class I samples and implemented a manual review policy to override putative FPs to negatives. In the production phase, we evaluated the policy in 58,054 samples screened over an eight-month period. As we routinely identify samples with FFpos >> FFinf (Class II FFD) because of interfering maternal copy number variants (CNVs), we also measured the frequency of Class II FFDs in our production cohort. We restricted samples to singleton pregnancies and sought outcomes for all positive results and 10% of negative results. RESULTS: In training, we identified simple criteria for identifying FPs: >6% FFinf and FFpos/FFinf < 33%. After flagging putative FPs, reviewers confirm the absence of subchromosomal CNVs before overriding the result to negative. Training outcome data confirmed that these criteria would correctly change 16 FPs to negative without reducing sensitivity for 142 TPs. In production, 155 Class I samples were flagged for manual review; of these, 154 were overridden to negative and none have been reported as false negative. We identified 81 Class II FFDs (FFpos> FFinf, Table 1 ) among production samples, which prompted manual review and inclusion of report notes indicating suspected maternal findings. CONCLUSION: Accounting for FF outliers in the bioinformatics and result-review processes reduces the FP rate of NIPS. Further, we routinely use the measures to assist dedicated algorithms that identify subchromosomal aneuploidies and maternal CNVs.
916 A data-driven approach for determining optimal content for expanded carrier screening panels OBJECTIVE: To use a data-driven approach to evaluate the impact of American College of Obstetrics and Gynecology (ACOG) diseaseinclusion criteria for expanded carrier screening (ECS) panels as recommended in clinical guidelines. STUDY DESIGN: De-identified data from 56,281 patients who underwent ECS on a 176-condition panel were analyzed to assess how exclusion of diseases that did not meet inclusion criteria impacted the rates of detection of carriers and at-risk couples. Postulating that a disease is worthy of screening only if the clinical sensitivity is high, we developed a quantitative modeling framework that estimates the achievable clinical detection rate of carriers by calculating the probability that sufficient reported cases exist in the literature to interpret the pathogenicity of observed variants. RESULTS: 170 (97%) of the 176 conditions met at least six of the seven ACOG disease-inclusion criteria, including those relating to disease severity and availability of prenatal diagnosis. Limiting an ECS panel to conditions meeting at least these six criteria would reduce identification of at-risk couples by 2%. The one remaining criterion, that an ECS panel disease must have a carrier frequency above 1-in-100, can be interpreted in different ways, as carrier frequencies vary widely by ethnicity. Depending on the definition used, the criterion is satisfied by between 13 (7%) and 38 (22%) conditions, and requiring that this criterion be met would reduce identification of at-risk couples by between 8% and 46%. Seeking a clinically relevant carrier-frequency cutoff, we modeled disease-level clinical sensitivity and found that a disease with a carrier frequency as low as 1 in 1,000 could still achieve a clinical sensitivity of 90%. CONCLUSION: In order for an ECS panel to be clinically meaningful to patients, disease inclusion criteria are needed. However, by analyzing data from a large patient cohort, we demonstrate that the 1-in-100 carrier-frequency threshold suggested by ACOG has considerable clinical consequences. When strictly enforced, it limits at-risk couple detection, suggesting that the recommendation of this threshold should be revisited. To that end, we propose an alternative criteria that can identify when a disease is too rare to include in an ECS panel based on its estimated clinical sensitivity. 
